Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Status:
Terminated
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to understand the safety, pharmacokinetics and
pharmacodynamics of a single dose of TT30 (ALXN1102 and ALXN1103 formulations) when given IV
(through a vein) or SC (under the skin) to patients with PNH.